
Yvonne Diaz/ey.com
May 19, 2025, 16:02
Yvonne Diaz: Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC
Yvonne Diaz, EY Global Media Relations and Social Media Director, shared a post on X:
“Promising signals from the ALEK-B ph 2 trial: combining alectinib with bevacizumab achieved 97.1% 12-mo PFS and median PFS of 39.6 months in ALK+ NSCLC.
Intracranial control also notably strong.
Could this combo help overcome resistance in more aggressive ALK variants?.”
Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial
Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell
You can read the Full Article on Nature Communications.
More posts featuring Yvonne Diaz.
alectinib
Alexandra Garcilazo-Reyes
Andres F. Cardona
Bevacizumab
cancer
David Dávila-Dupont
Eduardo Rios-Garcia
Enrique Caballé-Pérez
Graciela Cruz-Rico
Jordi Remon
Luis Cabrera-Miranda
Luis Lara-Mejía
Lung cancer
Maritza Ramos-Ramírez
NSCLC
OncoDaily
Oncology
Oscar Arrieta
Rafael Rosell
Yvonne Diaz
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 19, 2025, 15:51
May 19, 2025, 15:42
May 19, 2025, 15:41
May 19, 2025, 15:25
May 19, 2025, 14:10